Anbogen Therapeutics, Inc. Stock Price

Anbogen Therapeutics, Inc. develops precision anti-cancer drugs and conducts research and development in oncology. The company develops precision oncology drugs, including clinical-stage assets such as ABT-101 for non-small cell lung cancer with HER2 exon20 insertion mutations and ABT-301 for metastatic colorectal cancer in combination with anti-PD-1 therapies. It conducts clinical trials to evaluate the safety, tolerability, and efficacy of its drug candidates, including combination therapies with immune checkpoint inhibitors. The company manages a research and development platform and pipeline for advancing cancer therapies and collaborates with pharmaceutical companies for drug-supply agreements. Anbogen Therapeutics serves pharmaceutical companies, oncology-focused biopharmaceutical companies, diagnostic firms, research institutes, and clinical research organizations. The company was founded in 2019 and is based in Taipei, Taiwan.